Alnylam Pharmaceuticals (ALNY) Stock Price vs Revenue
Open the interactive overlay on autario.com.
Between Q2 2020 and Q2 2021, Alnylam's revenue grew 99.2% from $345.2M to $687.5M, while the stock price rose 14.5% from $148.11 to $169.52 over the same period. Despite nearly doubling revenue, the stock's more modest price appreciation indicates valuation compression—investors paid less per dollar of revenue at the later date. Over the broader 22-year window from June 2004 to June 2026, the stock rallied from $7.00 to $285.38 while revenue data shows acceleration from sub-$100M annual rates in 2017-2018 to $687.5M by mid-2021, reflecting a strong 0.81 correlation between the two metrics. The company's most recent stock price of $285.38 as of June 2, 2026 represents continued appreciation, though the latest revenue filing available is from June 30, 2021.
Trailing-12-month Revenue was $687.5M as of 2021-06-30, +99% year over year. The stock moved +14% over the same window ($148.11 -> $169.52). The stock is now cheaper relative to Revenue than a year ago (multiple compression).
Latest close: 287.77 USD (2026-06-02).
Revenue | recent SEC reports
| Report date | Revenue | Period |
|---|
| 2021-06-30 | 687.5M USD | Q2 10-Q |
| 2021-03-31 | 570.9M USD | Q1 10-Q |
| 2020-12-31 | 492.9M USD | FY 10-K |
| 2020-09-30 | 401.0M USD | FY 10-K |
| 2020-06-30 | 345.2M USD | Q2 10-Q |
| 2020-03-31 | 285.9M USD | Q1 10-Q |
| 2019-12-31 | 219.8M USD | FY 10-K |
| 2019-09-30 | 169.1M USD | FY 10-K |
Sources: autario.com/data/stock-alny-alnylam-pharmaceuticals-daily-prices · autario.com/data/alnylam-pharmaceuticals-revenue-sec-filings | data verified and hosted on autario.com.